Compare PulteGroup, Inc. (PHM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs Sanofi SA — how do they compare? PulteGroup, Inc. trades at $112.17 (market cap $21.63B), while Sanofi SA trades at $40.14 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 4.4× PulteGroup, Inc.'s market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold PulteGroup, Inc. for 91 Days and Sanofi SA for 94 Days on average.
| PHM | SNY | |
|---|---|---|
Market Cap | $21.63B | $95.18B |
Volume | 2,324,729 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $52.34 |
52-Week Low | $110.11 | $39.51 |
Typical Hold Time | 91 Days | 94 Days |
Enterprise Value | $22.04B | $114.48B |
Dividend Yield | 0.92% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $111.76, down 0.51% amid broader housing sector pressure from rising mortgage rates. The stock shows bearish technical signals with support near $109-110, while fundamentals reveal solid profitability (11.62% net margin) but declining revenue and earnings trends. Recent quarters show mixed earnings performance with two misses and one beat against expectations.
PHM presents a value opportunity with attractive valuation multiples (P/E 11.6) and analyst consensus target of $139.80, but faces headwinds from housing affordability concerns and volatile cash flows. The stock's near-term trajectory depends on Q3 2026 earnings results due October 22, 2026, with institutional ownership remaining stable despite sector challenges.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
